Cellectar Biosciences (CLRB) Misses Q2 EPS by 9c

Cellectar Biosciences (NASDAQ: CLRB) reported Q2 EPS of ($0.57), $0.09 worse than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Cellectar Biosciences (CLRB) click here.

You May Also Be Interested In

• Activist investors push Seer, Inc. to disclose go-private timeline
• Axos Financial (AX) PT Raised to $120 at Benchmark
• Benchmark Reiterates Buy Rating on NANO Nuclear Energy (NNE)